AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05539131 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)
Description: Transcranial direct current stimulation (tDCS) suppresses excitability and regulates excitability of neurons by injecting a small amount of current through electrodes attached to the scalp.
Study NCT05539131 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)
Description: Transcranial direct current stimulation (tDCS) suppresses excitability and regulates excitability of neurons by injecting a small amount of current through electrodes attached to the scalp.
Study NCT06525246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-7475
Description: Specified dose, once daily
Study NCT06525246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib Mesylate
Description: Specified dose, once daily
Study NCT05032755 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPECTRUM NRC 102/103 investigational cigarettes
Description: Very low nicotine content (nonmenthol/menthol) SPECTRUM investigational cigarettes
Study NCT05032755 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SPECTRUM NRC 600/601 investigational cigarettes
Description: Normal nicotine content (nonmenthol/menthol) SPECTRUM investigational cigarettes
Study NCT06094205 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BrainGate Neural Interface System
Description: Placement of the BrainGate2 sensor(s) into the speech-related cortex
Study NCT05882318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eCoin Peripheral Neurostimulator System
Description: The eCoin device is a leadless, coin-sized tibial neurostimulator for treatment of urgency urinary incontinence. It emits a dome-shaped electrical field to deliver low-duty cycle stimulation to the tibial nerve. The device is to be implanted under local anesthetic in the lower leg, and once activated delivers automatic 30-minute treatment sessions without the need for patient management.
Study NCT04077281 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Coordinated care
Description: * Clinical Pharmacology \& Toxicology consult~* CPT team completes detailed circle of care communication~* Telemedicine followup by CPT team (approximately 48 hrs post-discharge \& 1 week to1 month post-discharge)
Study NCT05889390 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oncotherm EHY-2030
Description: Oncotherm EHY-2030 is a non-invasive electromagnetic devices with known anti-tumoral effects. It operates in a precision capacitive coupled impedance matched way, working on a radiofrequency of 13.56 MHz. mEHT exploits various biophysical differences of cancer cells. For example, energy absorption on the membrane rafts is different than those of healthy host cells, and damage-associated molecular patterns (DAMPS) will also occur leading to programmed or immunogenic tumor cell death. mEHT can enhance DNA fragmentation of tumor cells, increase the fraction of cells with low mitochondrial membrane potential, increase the concentration of intracellular Ca2+, increase the Fas, c-Jun N-terminal kinases and MAPK/ERK signaling pathways, increase the expression of pro-apoptotic Bcl-2 family proteins and can up-regulate the expression of genes associated with the molecular function of cell death (EGR1, JUN, and CDKN1A) and silencing others associated with cytoprotective functions.
Study NCT05889390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: weekly paclitaxel for 12 weeks
Study NCT05889390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: weekly paclitaxel for 12 weeks
Study NCT05889390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: added to weekly paclitaxel if patient has triple-negative breast cancer
Study NCT05889390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: added to weekly paclitaxel if patient has triple-negative breast cancer
Study NCT05889390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide/Doxorubicin
Description: according to the AC protocol
Study NCT05889390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide/Doxorubicin
Description: according to the AC protocol
Study NCT05889390 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Breast cancer removal surgery
Description: Either breast-conserving surgery or total mastectomy after the neoadjuvant chemotherapy with or without mEHT (if feasible)
Study NCT05889390 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast cancer removal surgery
Description: Either breast-conserving surgery or total mastectomy after the neoadjuvant chemotherapy with or without mEHT (if feasible)
Study NCT04713514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSE2101
Description: subcutaneous injection on day 1, every 3 weeks for 7 doses then every 6 weeks up to week 48 and then every 12 weeks until intolerance, disease progression, or up to 2 years.
Study NCT04713514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 25 MG/ML [Keytruda]
Description: 400 mg IV infusion on day 1 every 6 weeks until intolerance, disease progression, or up to 2 years.
Study NCT06384430 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Shoulder functional tests and ultrasound
Description: On the day of the study, demographic data will be collected from patients with a clinical diagnosis of impingement and who agree to participate in the study, then DASH and Constant Murley scores will be calculated and subacromial bursa thickness, supraspinatus tendon thickness, acromiohumeral distance, supraspinatus tendon thickness/acromiohumeral distance ratio will be calculated on ultrasound.
Study NCT05939947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALE.F02
Description: Continuous intravenous (IV) infusion administered once every second week to a total of 3 doses.
Study NCT05939947 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Continuous intravenous (IV) infusion administered once every second week to a total of 3 doses.
Study NCT06674551 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block and Axillary nerve block
Description: A linear ultrasound probe will be placed in a sagittal plane at the superior medial border of the scapula. The probe will be moved laterally and then placed parallel to the scapular spine. when the needle tip contacts the bone just medial to the spinoglenoid notch and after confirmation of absence of vascular structure by color Doppler, 10 ml of 0.5% bupivacaine will be injected with aspiration every 3 ml to avoid intravascular injection and the spread of the local anaesthetic
Study NCT06674551 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interscalene Nerve Block
Description: The ultrasound probe will be placed in the supraclavicular fossa in a transverse orientation, aimed caudad into the thoracic cavity, to visualize the brachial plexus near the subclavian artery. Once identified, the plexus will be followed cephalad where it is found within the brachial plexus fascial sheath in the interscalene groove.
Study NCT05893732 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Intensity Laser Therapy (HILT)
Description: Participants will undergo HILT treatment using a diode laser device (wavelength: 1064 nm; power: 12 W; peak power: 50 W; energy density: 600 J/cm²; spot size: 1 cm²; pulse duration: 200 μs; pulse frequency: 10 Hz) applied in continuous mode. The laser probe will make contact with the skin over the LFCN entrapment site at three specific points: (a) the inguinal ligament, (b) the point of maximum tenderness along the nerve pathway, and (c) the mid-point between the ASIS and the lateral border of the patella. Each point will be treated for 1 minute and 40 seconds, totaling a 5-minute session. Participants will undergo 12 sessions in total, with three sessions per week for four weeks.
Study NCT05893732 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham High-Intensity Laser Therapy (Sham HILT)
Description: Participants will undergo sham HILT treatment using an identical laser device with no active laser output, following the same treatment protocol as the HILT group. The laser probe will make contact with the skin over the LFCN entrapment site at the same three specific points as the HILT group. Each point will be treated for 1 minute and 40 seconds, totaling a 5-minute session. Participants will undergo 12 sessions in total, with three sessions per week for four weeks.
Study NCT05907980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ROSE12
Description: ROSE12 as a IV infusion
Study NCT04228276 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Description: rTMS is a non-invasive procedure in which administering a transient magnetic field induces electrical currents in specific, targeted brain regions. The intervention (active and sham) will be administered in 8 sessions across 2 weeks. The brain region targeted is the dorsolateral prefrontal cortex.
Study NCT04228276 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Description: rTMS is a non-invasive procedure in which administering a transient magnetic field induces electrical currents in specific, targeted brain regions. The intervention (active and sham) will be administered in 8 sessions across 2 weeks. The brain region targeted is the dorsolateral prefrontal cortex.
Study NCT05877547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efinopegdutide
Description: Subcutaneous (SC) injection in dose-escalation regimens potentially including doses of 2 mg, 4 mg, 7 mg, and 10 mg
Study NCT05877547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: SC injection in a dose-escalation regimen of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg
Study NCT05877547 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC injection of matching placebo
Study NCT05320796 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: upper endoscopy
Description: A wireless BRAVO™ - pH monitoring device is placed and the participant is discharged with ongoing pH monitoring. The next day, the participant is randomized to either receive Esomeprazol MUT Sandoz® tablet 40mg or Esomeprazol MUT Sandoz® 40mg in solution. Serum concentration of Esomeprazol is measured at 0, 60 and 120 minutes and the patient is discharged after. After 48 hours of pH monitoring, the patient returns the BRAVO™ - recorder, adverse events are assessed and the study is terminated.
Study NCT05320796 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: upper endoscopy
Description: A wireless BRAVO™ - pH monitoring device is placed and the participant is discharged with ongoing pH monitoring. The next day, the participant is randomized to either receive Esomeprazol MUT Sandoz® tablet 40mg or Esomeprazol MUT Sandoz® 40mg in solution. Serum concentration of Esomeprazol is measured at 0, 60 and 120 minutes and the patient is discharged after. After 48 hours of pH monitoring, the patient returns the BRAVO™ - recorder, adverse events are assessed and the study is terminated.
Study NCT05907980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab as a IV infusion
Study NCT05272449 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sleep apnea diagnosis
Description: Split-night
Study NCT03816319 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study NCT03816319 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT03816319 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT03816319 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT03816319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UAE Inhibitor TAK-243
Description: Given IV
Study NCT04843371 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Photoplethysmography
Description: Photoplethysmography (PPG) is a non-invasive technique that can detect volumetric changes in the peripheral blood. It only requires skin contact and relies on light absorption. PPG is a good indicator of the cardiovascular dynamics in the human body. PPG has been incorporated into various new smartphones and wearable devices such as, smartwatches and fitness wristbands making it readily available to all consumers. This sensor can record biometrics such as, heart rate, blood pressure, oxygen saturation, etc.
Study NCT04752189 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Replicating Effective Programs (Enhanced REP)
Description: Enhanced REP includes 1. a tailored MMH curriculum, 2. tailored training, and 3. ongoing provider consultation or facilitation to support implementation.
Study NCT04752189 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard implementation
Description: The standard implementation of the Michigan Model for Health is consistent with Standard REP and includes the curriculum materials, standard training, and as-needed technical assistance.
Study NCT05463003 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Berberine
Description: A single dose of 1000 mg berberine in two capsules will be administered with 250 ml of still water in the overnight fasting condition. A total of 12 blood samples will be taken at defined time points (baseline, 1; 1.5; 2; 3; 4; 5; 6; 8; 10; 24; 48 h). At each time point, blood will be collected in 2x 7.5 ml tubes for collecting serum and plasma samples to determine berberine, its metabolites and biomarkers of OCT1 transport and CYP2D6 enzymatic activity
Study NCT06091332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus is an mTORC1 inhibitor that has received approval from the U.S. Food and Drug Administration (FDA) and has recently been successfully used to treat lymphatic malformations and venous/lymphatic malformations associated with the same PIK3CA GOF mutations.
Study NCT06091332 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Starch flake
Description: The placebo is composed of starch material and is formulated at 0.5 grams per tablet.
Study NCT05067907 — intervention group
Intervention type: PROCEDURE
Intervention: Early physiotherapy
Description: Respiratory physiotherapy included:~1. early and functional mobilization: passive and active mobilization, muscle strengthening, improving independence in activities of daily living (ADL), sitting out of bed, standing, walking;~2. patient positioning to achieve better ventilation/perfusion ratio and gas exchange;~3. airway clearance;~4. aerosol administration;~5. invasive mechanical ventilation weaning;~6. use of non-invasive mechanical ventilation (NIMV) and continuous positive airway pressure (CPAP);~7. tracheostomy management and weaning;~8. swallowing assessment;~9. management of oxygen delivery;~10. lung expansion;~11. patient assessment and functional scale administration.
Study NCT04925271 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: X-Tack
Description: The mucosal or submucosal defect is closed with X-Tack.
Study NCT04925271 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Overstitch
Description: The mucosal or submucosal defect is closed with Overstitch.
Study NCT05158660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial duplex sonography
Description: it is an imaging device that will measure the intracerebral hematoma expansion
Study NCT05187325 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: there is no intervention
Study NCT04547179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab-Vfrm
Description: Patients will receive three injections of Ajovy® if in the corresponding arm of the study.
Study NCT04547179 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BLAfit®
Description: Usage of the BLAfit device, a fixed orthotic appliance that allows users to tone facial muscles with one minute usage per day
Study NCT04547179 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Patients will receive three injections of saline if in the corresponding arm of the study. This is a placebo meant to simulate the Ajovy® injection.
Study NCT06678568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telemedicine follow-up in 3rd week
Description: Intervention group will be appointed with telemedicine follow-up in 3rd week after injury, instead of hospital follow-up visit.
Study NCT06685770 — intervention group
Intervention type: OTHER
Intervention: Mini mental state assessment test
Description: Breast cancer is a very common and important disease in the female population around the world. Anesthesia management during surgery for this disease in the postoperative period should be carefully planned. It will be important to examine the neurocognitive effects of anesthesia management in the postoperative period in this patient group. Today, inhaler and total intravenous anesthesia have advantages as well as disadvantages. It would be valuable to examine its neurocognitive effects in this patient group. In this study, the frequently used Mini mental state assessment test and Mini-cog test will be used.With mini mental state assessment, the patient is asked a number of simple questions to evaluate cognitive functions and each question has certain points. Changes in these score levels preoperatively and postoperatively will be compared within each patient. At the end of the study, preoperative and postoperative changes will be compared statistically between the groups.
Study NCT05314062 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FeSO4
Description: 2 FeSO4 supplements containing 27 mg elemental iron/supplements (54 mg total iron)
Study NCT05314062 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ao iron
Description: 2 Ao iron supplements containing 27 mg elemental iron/supplements (54 mg total iron)
Study NCT06174064 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Broadband Light treatment
Description: While shielding the eyes, multiple passes of broadband light will be applied to the upper cheeks and eyelids after applying topical lidocaine.
Study NCT06174064 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham broadband light treatment
Description: The light will be occluded on the usual BBL device so that no treatment is delivered but the preparation and procedure will otherwise be the same.
Study NCT05910177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Karelizumab combined with etoposide and cisplatin
Description: Karelizumab：200 mg，ivgtt，D1，q3w； Cisplatin：75 mg/m2，ivgtt，D1，q3w； Etoposide：100 mg/m2，ivgtt，D1\~3，q3w
Study NCT05417243 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trauma life support training
Description: Clusters are randomised for their residents to be trained in one of two trauma life support training programs or to continue providing standard care.
Study NCT06468722 — intervention group
Intervention type: BEHAVIORAL
Intervention: Exercise-based rehabilitation
Description: Patients performed regular physical exercise during inpatient rehabilitation
Study NCT04933240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen Citrate 10Mg Tab
Description: nonsteroidal antiestrogen for oral administration in 10 mg tablets. Each tablet contains 15.2 mg of tamoxifen citrate which is equivalent to 10 mg of tamoxifen.
Study NCT04933240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol
Description: estradiol tablets for oral administration contains 1 mg of micronized estradiol per tablet.
Study NCT04933240 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A sugar tablet that does not contain any active medicine
Study NCT05568173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Boxing Training
Description: In addition to boxing training, stretching exercises and posture training will be given at BG. A physiotherapist with a boxing training certificate will perform modified boxing training that progresses according to the degree of difficulty. There will be four difficulty levels. The complexity of the exercises will increase at 2-week intervals as the patient progresses. As a result, 0-2 weeks 1st level, 2-4 weeks 2nd level, 4-6 weeks 3rd level and 6-8 weeks 4th level exercises will be done.~In the first level, patients will be asked to punch the fixed boxing mat hanging on the wall with various instructions. Then, in levels 2-4, target gloves and heavy punching bags will be used to increase the difficulty level. As the sessions progress, the resistance and frequencies between the levels will be increased by the physiotherapist. There will be 3 sessions of 30-minute boxing training per week for 8 weeks at BG.